• LAST PRICE
    80.3700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    75.7400/ 1
  • Ask / Lots
    85.2600/ 1
  • Open / Previous Close
    0.0000 / 80.3700
  • Day Range
    ---
  • 52 Week Range
    Low 38.7800
    High 89.3900
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 80.615
TimeVolumeNUVL
09:32 ET148179.23
09:34 ET10079.27
09:39 ET10079.26
09:41 ET10079.6
09:50 ET30080.01
09:52 ET10080.2
09:56 ET30079.89
09:57 ET60079.845
09:59 ET10080.065
10:06 ET20080.005
10:08 ET30080.38
10:10 ET30080.24
10:12 ET20080.18
10:17 ET47980.1
10:19 ET10080.03
10:21 ET40080.2
10:24 ET30480.35
10:28 ET10080.22
10:30 ET20080.315
10:32 ET1087580.46
10:35 ET10080.59
10:39 ET30080.6
10:42 ET10080.37
10:46 ET30080.32
10:48 ET80080.095
10:50 ET40080.085
10:51 ET20080.23
10:55 ET30080.22
10:57 ET10080.325
11:04 ET10080.14
11:13 ET10080.25
11:15 ET11680.02
11:18 ET30080.39
11:20 ET10080.38
11:22 ET20080.17
11:24 ET10080.13
11:29 ET30080.15
11:33 ET30080.17
11:36 ET50080.29
11:47 ET30080.15
11:49 ET40080.175
11:51 ET10080.13
11:54 ET10080.0988
11:56 ET10080.23
12:05 ET10080.15
12:07 ET40080.16
12:14 ET20080.4
12:16 ET30080.37
12:23 ET10080.21
12:25 ET10080.31
12:32 ET30080.21
12:34 ET160080.33
12:41 ET10080.3
12:50 ET60080.36
12:54 ET70080.46
01:01 ET30080.43
01:12 ET10080.33
01:15 ET10080.49
01:19 ET10080.4
01:21 ET70080.58
01:24 ET40080.54
01:26 ET20080.62
01:32 ET30080.68
01:33 ET40080.55
01:35 ET10080.57
01:37 ET10080.66
01:42 ET10080.57
01:46 ET40080.62
01:48 ET50080.73
01:51 ET30580.59
01:53 ET30080.58
01:55 ET10080.67
02:04 ET40080.63
02:06 ET10080.535
02:08 ET10080.64
02:09 ET120080.59
02:11 ET10080.57
02:15 ET60080.705
02:18 ET70080.72
02:20 ET100080.79
02:22 ET10080.79
02:27 ET30080.81
02:31 ET100080.785
02:33 ET170080.97
02:36 ET70080.96
02:38 ET30080.91
02:40 ET235280.875
02:42 ET20080.87
02:44 ET40080.92
02:45 ET70080.845
02:47 ET60080.9
02:49 ET50080.825
02:51 ET323180.9
02:54 ET50080.945
02:56 ET71280.945
02:58 ET20080.9425
03:00 ET20080.99
03:02 ET100080.55
03:03 ET50080.495
03:05 ET423080.75
03:09 ET10080.77
03:12 ET10080.56
03:14 ET80980.67
03:18 ET10080.65
03:20 ET10080.67
03:21 ET110080.64
03:23 ET198380.615
03:25 ET10080.56
03:27 ET160080.68
03:30 ET40080.495
03:32 ET30080.59
03:34 ET90080.595
03:36 ET10080.575
03:38 ET80080.55
03:39 ET120180.535
03:41 ET173680.515
03:43 ET481780.4
03:45 ET130080.025
03:48 ET20079.92
03:50 ET244979.82
03:52 ET390580.04
03:54 ET565780.17
03:56 ET350080.38
03:57 ET716680.37
03:59 ET1405580.37
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNUVL
Nuvalent Inc
5.2B
-33.4x
---
United StatesVKTX
Viking Therapeutics Inc
5.3B
-51.4x
---
United StatesIBRX
Immunitybio Inc
5.0B
-6.9x
---
United StatesKRYS
Krystal Biotech Inc
5.2B
96.0x
---
United StatesSMMT
Summit Therapeutics Inc
5.6B
-48.4x
---
United StatesMDGL
Madrigal Pharmaceuticals Inc
6.0B
-12.1x
---
As of 2024-06-26

Company Information

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

Contact Information

Headquarters
One Broadway, 14th FloorCAMBRIDGE, MA, United States 02142
Phone
857-357-7000
Fax
302-655-5049

Executives

Non-Executive Independent Chairman of the Board
Anna Protopapas
President, Chief Executive Officer, Director
James Porter
Chief Financial Officer, Treasurer
Alexandra Balcom
Chief Development Officer
Darlene Noci
Chief Medical Officer
Christopher Turner

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.2B
Revenue (TTM)
$0.00
Shares Outstanding
64.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.41
Book Value
$10.94
P/E Ratio
-33.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.